Alexion Pharmaceuticalsのショートレシオ
Alexion Pharmaceuticalsのショートレシオは何ですか。
Alexion Pharmaceuticals Inc.のショートレシオは4.24です。
ショートレシオの定義は何ですか。
短期比率は、 短期売却株式数を日々の平均金額で割ったものです。
Short ratio is calculated by dividing the number of shares sold short by the average daily trading volume, generally over the last 30 trading days. The ratio represents the number of days it takes short sellers on average to repurchase all the borrowed shares. The ratio is used by both fundamental and technical traders to identify trends.
The percentage represents the number of days it takes short sellers on average to repurchase all the borrowed shares. Short selling is the practice of selling securities or other financial instruments that are not currently owned, and subsequently repurchasing them. In the event of an interim price decline, the short seller profits, since the cost of (re)purchase is less than the proceeds received upon the initial (short) sale. Conversely, the short position closes out at a loss if the price of a shorted instrument rises prior to repurchase. A high short ratio can be an indicator that there will be some buying pressure on the security that would increase its price.
NASDAQのセクタHealth Careにおけるショートレシオの企業と比べるAlexion Pharmaceuticals
Alexion Pharmaceuticalsは何をしますか。
Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. As a leader in rare diseases for more than 25 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D) as well as the first and only approved Factor Xa inhibitor reversal agent. In addition, the company is developing several mid-to-late-stage therapies, including a copper-binding agent for Wilson disease, an anti-neonatal Fc receptor (FcRn) antibody for rare Immunoglobulin G (IgG)-mediated diseases and an oral Factor D inhibitor as well as several early-stage therapies, including one for light chain (AL) amyloidosis, a second oral Factor D inhibitor and a third complement inhibitor. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology, ophthalmology and acute care. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.
Alexion Pharmaceuticalsと類似のショートレシオ
- Cardiovascular Systemsのショートレシオは4.23です。
- TMXのショートレシオは4.23です。
- Canadian Pacific Railwayのショートレシオは4.23です。
- Avangrid Incのショートレシオは4.23です。
- Hudson Executive Investmentのショートレシオは4.23です。
- Antero Midstream Corpのショートレシオは4.23です。
- Alexion Pharmaceuticalsのショートレシオは4.24です。
- Beasley Broadcast Incのショートレシオは4.25です。
- Justのショートレシオは4.25です。
- PetIQ Incのショートレシオは4.25です。
- Zoom Video Communications Incのショートレシオは4.25です。
- Strategem Capitalのショートレシオは4.25です。
- Immunogenのショートレシオは4.25です。